Gancotamab clinical trials
Also written MM-302.
How each study uses gancotamab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MM-302
- 2
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Merrimack Pharmaceuticals (2) · Pamela Munster (1)
Studies
Open first, then newest update. How each study uses gancotamab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain MetsWithdrawnEarly Phase 1Pamela MunsterNCT02735798Written as MM-302Report a problem
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTerminatedPhase 2/3Merrimack PharmaceuticalsNCT02213744Written as MM-302Report a problem
- Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast CancerStatus unknownPhase 1Merrimack PharmaceuticalsNCT01304797Written as MM-302 MonotherapyReport a problem
Tested with established drugs · 2 — they are given beside it
- 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain MetsWithdrawnEarly Phase 1Pamela MunsterNCT02735798Written as MM-302Report a problem
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsTerminatedPhase 2/3Merrimack PharmaceuticalsNCT02213744Written as MM-302Report a problem
Tested in a combination · 1 — another drug in the study is under test too
Codes
What other systems call gancotamab · ClinicalTrials.gg INT000814
- MeSH (NLM) C000624282gancotamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) S5Z216QNO6GANCOTAMABConfirmed FDA, NLM
- NCI Thesaurus C170020GancotamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000624282 | gancotamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | S5Z216QNO6 | GANCOTAMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C170020 | Gancotamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.